EntryPoint Capital’s Regenxbio RGNX Stock Holding History

EntryPoint Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,538	Closed	-$96.9K	–	912
2024 Q4	$96.9K	Buy	+12,538	New	+$118K	0.04%	671

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

EntryPoint Capital's RGNX Position: Q1 2025 in Review

EntryPoint Capital sold out of Regenxbio (RGNX) in Q1 2025, closing a stake of 12,538 shares — an estimated $96.9K sold.

EntryPoint Capital first reported a position in RGNX in Q4 2024 and held it in 1 quarter. The position peaked at $96.9K in Q4 2024. 164 funds tracked by Wall St. Rank hold RGNX as of Q1 2025.

EntryPoint Capital reported no remaining Regenxbio position as of Q1 2025 after selling out during the quarter.
EntryPoint Capital sold 12,538 Regenxbio shares in Q1 2025, an estimated $96.9K.
EntryPoint Capital first reported a position in Regenxbio in Q4 2024 and held it in 1 quarter.
EntryPoint Capital's Regenxbio position peaked at $96.9K in Q4 2024.
164 funds tracked by Wall St. Rank held Regenxbio as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.